Adlai Nortye collaborates with Lilly and Merck KGaA

Adlai Nortye Group (Nasdaq: ANL) has partnered with Eli Lilly (NYSE: LLY) and Merck KGaA (MRK: DE) for clinical trials involving cetuximab (Erbitux). The collaboration supports Adlai Nortye's Phase I trial for AN4035, evaluating it as a monotherapy and with cetuximab in specific cancer patients. The trial is sponsored by Adlai Nortye.

Original reporting
Published Oct 16, 2026, 8:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 12:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Adlai Nortye collaborates with Lilly and Merck KGaA — source image
Decision brief

The 30-second read

$ANLBullishMed
01

Why it matters

The collaboration validates the technology and may accelerate development timelines, offering upside for ANL while being a routine supply deal for Lilly and Merck KGaA.

02

Market read

First‑report of a multi‑partner oncology trial could spark short‑term buying in ANL; limited effect on the larger pharma partners.

03

What to watch

Potential regulatory hurdles for the ADC and competition from other ADC developers.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Adlai Nortye Group, a Singapore‑based clinical‑stage biotech, is advancing its first‑in‑class ADC AN4035 targeting RAS‑mutant tumors.

Company-level read

Ticker impact

$ANLBullishHigh confidence
Context

Adlai Nortye Group announced a clinical‑trial collaboration and supply agreement with Eli Lilly and Merck KGaA for its Phase I ADC trial.

Expected impact

likely upward pressure as investors price in the new collaboration and potential future milestones.

Evidence & confidence

First‑report of a multi‑partner clinical trial; biotech collaborations often trigger short‑term rally.

$LLYNeutralMedium confidence
Context

Eli Lilly entered a supply agreement with Adlai Nortye to provide cetuximab for a Phase I trial of ANL's ADC candidate.

Expected impact

minimal immediate impact; the deal is a modest supply contract rather than a major revenue source.

Evidence & confidence

Supply agreements are routine for large pharma and unlikely to move the stock materially.

Market effects

Highlights growing interest in ADC platforms within oncology biotech sector.

May boost sentiment for US‑listed biotech stocks and German pharma peers.

Shows cross‑border collaboration trends in cancer drug development.

Counterpoint

The trial is early‑stage; investors may overprice the partnership risk.

Key entities

  • Adlai Nortye Group

    Clinical‑stage biotech developing ADCs.

  • Eli Lilly

    Large pharma providing cetuximab for the trial.

  • Merck KGaA

    German pharma supplying cetuximab for the trial.

Related articles

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.

$LLYMed

Health Canada approves Eli Lilly’s GLP-1 pill for weight loss

Health Canada approved Eli Lilly's GLP-1 pill, Foundayo, for weight loss and Type 2 diabetes. The daily pill targets adults with obesity or overweight with related conditions. Eli Lilly expects pharmacy availability in January. Foundayo competes with Novo Nordisk's injectables and Rybelsus, a GLP-1 pill for diabetes only. The active ingredient, orforglipron, is a non-peptide GLP-1 receptor agonist.

$MRKMed

Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns

Merck (MRK) is discontinuing development of nemtabrutinib, an experimental BTK inhibitor acquired via its $2.7B purchase of ArQule, due to safety concerns identified in late-stage trials. The decision follows recommendations from a data monitoring committee and Merck's own review, leading to the halt of several Phase 3 studies in the BELLWAVE program. The drug was being evaluated for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.